Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients with Acute Myeloid Leukemia

John M. Pagel, Megan Othus, Guillermo Garcia-Manero, Min Fang, Jerald P. Radich, David A. Rizzieri, Guido Marcucci, Stephen A. Strickland, Mark R. Litzow, M. Lynn Savoie, Stephen R. Spellman, Dennis L. Confer, Jeffrey W. Chell, Maria Brown, Bruno C. Medeiros, Mikkael A. Sekeres, Tara L. Lin, Geoffrey L. Uy, Bayard L. Powell, Ruthee Lu BayerRichard A. Larson, Richard M. Stone, David Claxton, James Essell, Selina M. Luger, Sanjay R. Mohan, Anna Moseley, Harry P. Erba, Frederick R. Appelbaum

Research output: Contribution to journalArticle

Abstract

PURPOSE Patients with acute myeloid leukemia with high-risk cytogenetics in first complete remission (CR1) achieve better outcomes if they undergo allogeneic hematopoietic cell transplantation (HCT) compared with consolidation chemotherapy alone. However, only approximately 40% of such patients typically proceed to HCT. METHODS We used a prospective organized approach to rapidly identify donors to improve the allogeneic HCT rate in adults with high-risk acute myeloid leukemia in CR1. Newly diagnosed patients had cytogenetics obtained at enrollment, and those with high-risk cytogenetics underwent expedited HLA typing and were encouraged to be referred for consultation with a transplantation team with the goal of conducting an allogeneic HCT in CR1. RESULTS Of 738 eligible patients (median age, 49 years; range, 18-60 years of age), 159 (22%) had high-risk cytogenetics and 107 of these patients (67%) achieved CR1. Seventy (65%) of the high-risk patients underwent transplantation in CR1 (P, .001 compared with the historical rate of 40%). Median time to HCT from CR1 was 77 days (range, 20-356 days). In landmark analysis, overall survival (OS) among patients who underwent transplantation was significantly better compared with that of patients who did not undergo transplantation (2-year OS, 48% v 35%, respectively [P = .031]). Median relapse-free survival after transplantation in the high-risk cohort who underwent transplantation in CR1 (n = 70) was 11.5 months (range, 4-47 months), and median OS after transplantation was 14 months (range, 4-44 months). CONCLUSION Early cytogenetic testing with an organized effort to identify a suitable allogeneic HCT donor led to a CR1 transplantation rate of 65% in the high-risk group, which, in turn, led to an improvement in OS when compared with the OS of patients who did not undergo transplantation.

Original languageEnglish (US)
Pages (from-to)E464-E475
JournalJCO Oncology Practice
Volume16
Issue number6
DOIs
StatePublished - Jun 1 2020

ASJC Scopus subject areas

  • Health Policy
  • Oncology
  • Oncology(nursing)

Fingerprint Dive into the research topics of 'Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients with Acute Myeloid Leukemia'. Together they form a unique fingerprint.

  • Cite this

    Pagel, J. M., Othus, M., Garcia-Manero, G., Fang, M., Radich, J. P., Rizzieri, D. A., Marcucci, G., Strickland, S. A., Litzow, M. R., Lynn Savoie, M., Spellman, S. R., Confer, D. L., Chell, J. W., Brown, M., Medeiros, B. C., Sekeres, M. A., Lin, T. L., Uy, G. L., Powell, B. L., ... Appelbaum, F. R. (2020). Rapid Donor Identification Improves Survival in High-Risk First-Remission Patients with Acute Myeloid Leukemia. JCO Oncology Practice, 16(6), E464-E475. https://doi.org/10.1200/JOP.19.00133